ConductScience.org, home

Paper35280262

Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study.

Hauser RA and 11 others. Front Neurol, 2022. Cited by 14 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study. Papers, record 35280262. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35280262

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study.
PubMed
Journal
Front Neurol
PubMed
Year
2022
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
14
iCite
Relative citation ratio, by iCite
1.57
iCite
Revised in PubMed
2024-08-24
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hauser RARobert A
2Barkay HHadas
3Fernandez HHHubert H
4Factor SAStewart A
5Jimenez-Shahed JJoohi
6Gross NNicholas
7Marinelli LLeslie
8Wilhelm AAmanda
9Alexander JJessica
10Gordon MFMark Forrest
11Savola JMJuha-Matti
12Anderson KEKaren E

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References23

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125,069,517Deuterated drugs: where are we now?Expert Opin Ther Pat2014https://conductscience.org/library/papers/25069517PubMed
231,296,586Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia.J Neurol Neurosurg Psychiatry2019https://conductscience.org/library/papers/31296586PubMed
32,716,220Mortality rate of schizophrenic patients with tardive dyskinesia during 10 years: a controlled study.Keio J Med1989https://conductscience.org/library/papers/2716220PubMed
430,027,457Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management.Neurol Ther2018https://conductscience.org/library/papers/30027457PubMed
521,131,613Spectrum of tardive syndromes: clinical recognition and management.Postgrad Med J2011https://conductscience.org/library/papers/21131613PubMed
625,556,809Tardive dyskinesia (syndrome): Current concept and modern approaches to its management.Psychiatry Clin Neurosci2015https://conductscience.org/library/papers/25556809PubMed
732,720,245Management of Tardive Syndrome: Medications and Surgical Treatments.Neurotherapeutics2020https://conductscience.org/library/papers/32720245PubMed
829,454,494Historical perspectives on tardive dyskinesia.J Neurol Sci2018https://conductscience.org/library/papers/29454494PubMed
931,435,866Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia.Qual Life Res2019https://conductscience.org/library/papers/31435866PubMed
1024,262,160Tardive dyskinesia syndromes: current concepts.Parkinsonism Relat Disord2014https://conductscience.org/library/papers/24262160PubMed
111,979,705Tardive dyskinesia.West J Med1990https://conductscience.org/library/papers/1979705PubMed
1220,156,410Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.J Clin Psychiatry2010https://conductscience.org/library/papers/20156410PubMed
1329,433,808VMAT2 inhibitors for the treatment of tardive dyskinesia.J Neurol Sci2018https://conductscience.org/library/papers/29433808PubMed
1432,454,050VMAT2 inhibitors for the treatment of hyperkinetic movement disorders.Pharmacol Ther2020https://conductscience.org/library/papers/32454050PubMed
1530,306,450VMAT2 Inhibitors in Neuropsychiatric Disorders.CNS Drugs2018https://conductscience.org/library/papers/30306450PubMed
1620,869,622Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.Am J Geriatr Pharmacother2010https://conductscience.org/library/papers/20869622PubMed
1728,446,646Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.Neurology2017https://conductscience.org/library/papers/28446646PubMed
1828,146,614Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis.J Clin Psychiatry2017https://conductscience.org/library/papers/28146614PubMed
1919,011,586Ten year outcome of tardive dyskinesia during continuous treatment with first generation antipsychotics.Psychiatr Danub2008https://conductscience.org/library/papers/19011586PubMed
2010,770,457Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies.J Clin Psychopharmacol2000https://conductscience.org/library/papers/10770457PubMed

See all 23 references

Cited by11

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.

PMIDTitleJournalYearIn PapersSource
42,682,903Deutetrabenazine in Hyperkinetic Movement Disorders: VMAT2 Modulation From Choreiform Disorders to Hyperkinetic Dystonic Syndromes.J Cent Nerv Syst Dis2026https://conductscience.org/library/papers/42682903PubMed
42,487,657Tardive Dyskinesia Induced by Long-Acting Injectable Paliperidone Palmitate Once Every 3 Months in a Patient With Schizophrenia: A Case Report and Literature Review.Clin Case Rep2026https://conductscience.org/library/papers/42487657PubMed
41,981,317Efficacy and safety of different pharmacological interventions in the treatment of tardive dyskinesia: a systematic review and network meta-analysis.Eur J Clin Pharmacol2026https://conductscience.org/library/papers/41981317PubMed
41,122,869VMAT2 inhibitors for the treatment of tardive dyskinesia: a narrative review.CNS Spectr2025https://conductscience.org/library/papers/41122869PubMed
39,985,106Real-world safety analysis of deutetrabenazine post-marketing: a disproportionality study leveraging the FDA Adverse Event Reporting System (FAERS) database.BMC Pharmacol Toxicol2025https://conductscience.org/library/papers/39985106PubMed
39,935,362From assessment to intervention: evidence-based approaches in tardive dyskinesia.CNS Spectr2025https://conductscience.org/library/papers/39935362PubMed
39,825,184Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease.CNS Drugs2025https://conductscience.org/library/papers/39825184PubMed
38,969,949Efficacy and safety of different pharmacological interventions in the treatment of tardive dyskinesia: a systematic review and network meta-analysis.Eur J Clin Pharmacol2024https://conductscience.org/library/papers/38969949PubMed
38,557,959Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease.Neurol Ther2024https://conductscience.org/library/papers/38557959PubMed
38,131,057Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia.Ment Health Clin2023https://conductscience.org/library/papers/38131057PubMed
37,277,503Deuterium in drug discovery: progress, opportunities and challenges.Nat Rev Drug Discov2023https://conductscience.org/library/papers/37277503PubMed

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CYP2D61,565PubTator's text mininghttps://conductscience.org/library/genes/1565NCBI Gene
SLC18A26,571PubTator's text mininghttps://conductscience.org/library/genes/6571NCBI Gene

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35280262

GET https://conductscience.org/api/papers/v1/35280262/references?page=2